Top Picks 2026- Dynex Capital Inc. DX [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
The REIT's portfolio consists of high-quality borrowers with only 2% of its MBS holdings yielding above 6%, highlights Nancy Zambell , editor-in-chief of Cabot Money Club To get your FREE copy of the complete MoneyShow 2026 Top Picks Report, click here The real estate industry is seeing its fundamentals improving, including rising home inventory, stabilizing housing prices, and declining mortgage rates. The 30-year fixed mortgage rate was around 6.17% in late 2025, down almost a percentage point for the full year. For its third quarter, Dynex saw significant earnings growth, up 120.9% over the past year, an impressive improvement from its five-year average decline of 26.8% per year. Additionally, the REIT's net profit margin jumped to 76.1%. The REIT is trading at a below-industry P/E, 11.5x, and its investors enjoy a very attractive dividend yield, recently 14.9%. That's fantastic cash flow, in addition to potential share appreciation. More From MoneyShow.com: Top Picks 2
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.MarketBeat
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23GlobeNewswire
- Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline [Seeking Alpha]Seeking Alpha
- How The New Price Target Is Shaping The Axsome Therapeutics (AXSM) Investment Story [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 1/23/26 - Form 4
- 1/23/26 - Form 4
- 1/22/26 - Form 144
- AXSM's page on the SEC website